SOUTH SAN FRANCISCO, Calif. — August 8, 2025 — Leads & Copy — Surrozen Inc. (Nasdaq: SRZN) reported its second quarter financial results and business highlights, including the appointment of Daniel Chao, M.D., Ph.D., as Vice President of Clinical Development, and the formation of a Clinical Advisory Board.
The biotechnology company, which focuses on treatments that modulate the Wnt pathway for tissue repair and regeneration, particularly in eye diseases, highlighted that it remains focused on its ophthalmology pipeline, advancing lead candidates SZN-8141 and SZN-8143 to address retinal diseases, and expects to submit an Investigational New Drug (IND) application for SZN-8141 in 2026.
In May, Surrozen was granted U.S. Patent No. 12,297,278 for its SWAP™ technology, supporting SZN-8141 and SZN-8143. The Clinical Advisory Board includes Dr. Jeffrey Heier, Dr. Arshad Khanani, Dr. Carl Regillo, and Dr. Charles Wykoff.
The company presented preclinical data for SZN-8141 and SZN-8143 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Clinical Trials Summit (CTS), showcasing their ability to promote normal retinal vessel regrowth.
Craig Parker, President and CEO of Surrozen, said the company is encouraged by the momentum in its ophthalmology pipeline.
Financial highlights include cash and cash equivalents of $90.4 million as of June 30, 2025. Net income was $39.7 million, or $2.55 per share, compared to a net loss of $25.3 million in the same period of 2024.
Daniel Chao, M.D., Ph.D. Email: Investorinfo@surrozen.com
Source: Surrozen
